134 related articles for article (PubMed ID: 26592309)
21. Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs.
Barber KE; Bell AM; Travis King S; Parham JJ; Stover KR
Braz J Infect Dis; 2016; 20(6):631-634. PubMed ID: 27609214
[TBL] [Abstract][Full Text] [Related]
22. Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitis.
Chew FL; Soong TK; Shin HC; Samsudin A; Visvaraja S
J Ocul Pharmacol Ther; 2010 Apr; 26(2):219-22. PubMed ID: 20415627
[TBL] [Abstract][Full Text] [Related]
23. Multicenter in vitro comparison of piperacillin and nine other antibacterials against 1,629 clinical isolates.
Greenberg RN; Bowne DB; Gelfand M; Sathe SS
Clin Ther; 1990; 12(1):61-70. PubMed ID: 2183941
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic evaluation of piperacillin-tazobactam.
Hayashi Y; Roberts JA; Paterson DL; Lipman J
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
[TBL] [Abstract][Full Text] [Related]
25. In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa.
Maioli E; Debbia EA; Gualco L; Marchese A
New Microbiol; 2008 Jan; 31(1):37-46. PubMed ID: 18437840
[TBL] [Abstract][Full Text] [Related]
26. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Garneau JR; Valiquette L; Fortier LC
BMC Infect Dis; 2014 Jan; 14():29. PubMed ID: 24422950
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
28. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
Seifert H; Körber-Irrgang B; Kresken M;
Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
[TBL] [Abstract][Full Text] [Related]
29. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
30. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
Pultz MJ; Donskey CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):3044-5. PubMed ID: 17562802
[No Abstract] [Full Text] [Related]
31.
Stainton SM; Monogue ML; Nicolau DP
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28607019
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
[TBL] [Abstract][Full Text] [Related]
33. A kinetic study on the interaction between tazobactam (a penicillanic acid sulphone derivative) and active-site serine beta-lactamases.
Perilli M; Franceschini N; Bonfiglio G; Segatore B; Stefani S; Nicoletti G; Perez MM; Bianchi C; Zollo A; Amicosante G
J Enzyme Inhib; 2000; 15(1):1-10. PubMed ID: 10850951
[TBL] [Abstract][Full Text] [Related]
34. Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol.
Tschudin-Sutter S; Frei R; Widmer AF
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):286-7. PubMed ID: 21353954
[No Abstract] [Full Text] [Related]
35. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
36. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
[TBL] [Abstract][Full Text] [Related]
37. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
38. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Kim A; Sutherland CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
[TBL] [Abstract][Full Text] [Related]
39. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
Youssif E; Aseeri M; Khoshhal S
J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
[TBL] [Abstract][Full Text] [Related]
40. Enterobacter endophthalmitis: treatment with intravitreal tazobactam - piperacillin.
Singh TH; Pathengay A; Das T; Sharma S
Indian J Ophthalmol; 2007; 55(6):482-3. PubMed ID: 17951917
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
